Browse > Article

Human Papillomavirus Vaccine  

Lee, Yu-Jeung (Drug Information Research Institute, Sookmyung Women's University)
Publication Information
Biomolecules & Therapeutics / v.15, no.3, 2007 , pp. 133-136 More about this Journal
Human papillomavirus (HPV) infection is the most common sexually transmitted disease in the United States. An estimated 6.2 million people are infected with HPV every year. Randomized controlled studies consistently show that HPV vaccine is effective in preventing infection and HPV related cervical lesions. In June 2006, Gardasil (qadrivalent HPV recombinant vaccine) was approved by the FDA for use in females 9-26 years of age. This article reviews published data to evaluate the effectiveness of HPV vaccine for the prevention of cervical cancer.
cervical cancer; human papillomavirus vaccine; Gardasil;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Gardasil [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] prescribing information. (2006). Whitehouse Station, N.J
2 Harper D. M., Franco E. L., Wheeler C., Ferris D. G., Jenkins D., Schuind A., Zahaf T., Innis B., Naud P., De Carvalho N. S., Roteli-Martins C. M., Teixeira J., Blatter M. M., Korn A. P., Quint W. and Dubin G. (2004). Efficacy of a bivalent L1 viruslike particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364(9447), 1757-65   DOI   ScienceOn
3 Centers for Disease Control and Prevention. (2007). Genital HPV Infection - CDC Fact Sheet
4 FDA News. (2007) FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus
5 Frazer I. H. (1996). Immunology of papillomavirus infection. Curr. Opin. Immunol. 8(4), 484-91   DOI   ScienceOn
6 FUTURE II Study Group. (2007). Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356(19), 1991-3   DOI   ScienceOn
7 Munoz N., Castellsague X., de Gonzalez A. B. and Gissmann L. (2006). Chapter 1: HPV in the etiology of human cancer. Vaccine 24(S3), S1-10   DOI   ScienceOn
8 Koutsky L. A., Ault K. A., Wheeler C.M., Brown D. R., Barr E., Alvarez F. B., Chiacchierini L. M. and Jansen K. U. (2002). A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347(21), 1645-51   DOI   ScienceOn
9 Munoz N, Bosch F. X., Castellsague X., Díaz M., de Sanjose S., Hammouda D., Shah K. V. and Meijer C. J. (2004). Against which human papillomavirus types shall we vaccinate and screen? The international perspective. 111(2), 278-85   DOI   ScienceOn
10 Munoz N., Bosch F. X., de Sanjose S., Herrero R., Castellsague X., Shah K. V., Snijders P. J. and Meijer C. J. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348(6), 518-27   DOI   ScienceOn
11 Padilla-Paz L. A. (2005). Human papillomavirus vaccine: history, immunology, current status, and future prospects. Clin. Obstet. Gynecol. 48(1), 226-40   DOI   ScienceOn
12 Parkin D. M. and Bray F. (2006) Chapter 2: The burden of HPVrelated cancers. Vaccine 24(S3), S11-25
13 Trottier H. and Franco E. L. (2006). The epidemiology of genital human papillomavirus infection. Vaccine 24(S1), S4-15   DOI   ScienceOn
14 Wright T. C., Bosch F. X., Franco E. L., Cuzick J., Schiller J. T., Garnett G. P. and Meheus A. (2006). Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine 24(S3), S251-61   DOI   ScienceOn
15 Villa L. L., Costa R. L., Petta C. A., Andrade R. P., Ault K. A., Giuliano A. R., Wheeler C. M., Koutsky L. A., Malm C., Lehtinen M., Skjeldestad F. E., Olsson S. E., Steinwall M., Brown D. R., Kurman R. J., Ronnett B. M., Stoler M. H., Ferenczy A., Harper D. M., Tamms G. M., Yu J., Lupinacci L., Railkar R., Taddeo F. J., Jansen K. U., Esser M. T., Sings H. L., Saah A. J. and Barr E. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6(5), 271-8   DOI   ScienceOn